These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 36038916)

  • 1. New progress in diagnosis and treatment of pulmonary arterial hypertension.
    Zhang ZQ; Zhu SK; Wang M; Wang XA; Tong XH; Wan JQ; Ding JW
    J Cardiothorac Surg; 2022 Aug; 17(1):216. PubMed ID: 36038916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Cells in Pulmonary Arterial Hypertension.
    Ni S; Ji T; Dong J; Chen F; Feng H; Zhao H; Chen D; Ma W
    Heart Lung Circ; 2022 Jul; 31(7):934-943. PubMed ID: 35361533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary arterial hypertension and microRNAs--an ever-growing partnership.
    Wang Y; Xue XY; Liu YX; Wang KF; Zang XF; Wang J; Wang PL; Zhang J; Pan L; Zhang SY; Wang JX
    Arch Med Res; 2013 Oct; 44(7):483-7. PubMed ID: 24051036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stem cell therapy for pulmonary arterial hypertension: An update.
    Sun QW; Sun Z
    J Heart Lung Transplant; 2022 Jun; 41(6):692-703. PubMed ID: 35341679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAGGED-NOTCH3 signaling in vascular remodeling in pulmonary arterial hypertension.
    Zhang Y; Hernandez M; Gower J; Winicki N; Morataya X; Alvarez S; Yuan JX; Shyy J; Thistlethwaite PA
    Sci Transl Med; 2022 May; 14(643):eabl5471. PubMed ID: 35507674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA-SMILR modulates RhoA/ROCK signaling by targeting miR-141 to regulate vascular remodeling in pulmonary arterial hypertension.
    Lei S; Peng F; Li ML; Duan WB; Peng CQ; Wu SJ
    Am J Physiol Heart Circ Physiol; 2020 Aug; 319(2):H377-H391. PubMed ID: 32559140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models.
    Dickinson MG; Bartelds B; Borgdorff MA; Berger RM
    Am J Physiol Lung Cell Mol Physiol; 2013 Jul; 305(1):L1-14. PubMed ID: 23624788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
    Orriols M; Gomez-Puerto MC; Ten Dijke P
    Cell Mol Life Sci; 2017 Aug; 74(16):2979-2995. PubMed ID: 28447104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension.
    Dumas SJ; Bru-Mercier G; Courboulin A; Quatredeniers M; Rücker-Martin C; Antigny F; Nakhleh MK; Ranchoux B; Gouadon E; Vinhas MC; Vocelle M; Raymond N; Dorfmüller P; Fadel E; Perros F; Humbert M; Cohen-Kaminsky S
    Circulation; 2018 May; 137(22):2371-2389. PubMed ID: 29444988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Molecular Mechanisms Involved in the Medical Treatment of Pulmonary Arterial Hypertension.
    Martin de Miguel I; Cruz-Utrilla A; Oliver E; Escribano-Subias P
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of JAK2 protects mice against hypoxia-induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation.
    Zhang L; Wang Y; Wu G; Rao L; Wei Y; Yue H; Yuan T; Yang P; Xiong F; Zhang S; Zhou Q; Chen Z; Li J; Mo BW; Zhang H; Xiong W; Wang CY
    Cell Prolif; 2020 Feb; 53(2):e12742. PubMed ID: 31943454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Pathways in Pulmonary Arterial Hypertension.
    Shah AJ; Vorla M; Kalra DK
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of the adenosine A2A receptor confers pulmonary arterial hypertension and increased pulmonary vascular remodeling in mice.
    Xu MH; Gong YS; Su MS; Dai ZY; Dai SS; Bao SZ; Li N; Zheng RY; He JC; Chen JF; Wang XT
    J Vasc Res; 2011; 48(2):171-83. PubMed ID: 20938208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recommendations for the diagnosis and treatment of connective tissue disease associated pulmonary arterial hypertension in China].
    Zhang X; Zhao JL; Ding F; Yang J; Wang J; Zeng XF; Zhao Y
    Zhonghua Nei Ke Za Zhi; 2022 Nov; 61(11):1206-1216. PubMed ID: 36323561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline.
    Thomas M; Docx C; Holmes AM; Beach S; Duggan N; England K; Leblanc C; Lebret C; Schindler F; Raza F; Walker C; Crosby A; Davies RJ; Morrell NW; Budd DC
    Am J Pathol; 2009 Feb; 174(2):380-9. PubMed ID: 19116361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension.
    Goncharov DA; Kudryashova TV; Ziai H; Ihida-Stansbury K; DeLisser H; Krymskaya VP; Tuder RM; Kawut SM; Goncharova EA
    Circulation; 2014 Feb; 129(8):864-74. PubMed ID: 24270265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial cells in the pathogenesis of pulmonary arterial hypertension.
    Evans CE; Cober ND; Dai Z; Stewart DJ; Zhao YY
    Eur Respir J; 2021 Sep; 58(3):. PubMed ID: 33509961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug discovery focused on novel pathogenic proteins for pulmonary arterial hypertension.
    Satoh K
    J Cardiol; 2021 Jul; 78(1):1-11. PubMed ID: 33563508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension.
    Hadri L; Kratlian RG; Benard L; Maron BA; Dorfmüller P; Ladage D; Guignabert C; Ishikawa K; Aguero J; Ibanez B; Turnbull IC; Kohlbrenner E; Liang L; Zsebo K; Humbert M; Hulot JS; Kawase Y; Hajjar RJ; Leopold JA
    Circulation; 2013 Jul; 128(5):512-23. PubMed ID: 23804254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolyl-4 Hydroxylase 2 (PHD2) Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension in Mice and Humans Through Hypoxia-Inducible Factor-2α.
    Dai Z; Li M; Wharton J; Zhu MM; Zhao YY
    Circulation; 2016 Jun; 133(24):2447-58. PubMed ID: 27143681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.